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Abstract 
Objective 
 
 To compare performance of three continence management devices and absorbent pads 
used by men with persistent urinary incontinence (> 1yr)  post treatment for prostate 
cancer.  
 
Patients and Methods 
 
 Randomised, controlled trial of 56 men with one year follow up. 
 Three devices were tested for three weeks each: sheath drainage system, body-worn 
urinal, penile clamp.  Device and pad performance were assessed.   
 Quality of life (QOL) was measured at baseline and follow-up with the King’s Health 
Questionnaire.  
 Stated (intended use) and revealed (actual use) preference for  products was assessed   
 Value-for-money was gathered. 
 
Results 
Substantial and significant differences in performance were found: 
 
 Sheath: good for extended use (e.g. golf and travel) when pad changing is difficult.  
Good for keeping skin dry, not leaking, not smelling and convenient for storage and 
travel;  
 Body-worn urinal: generally rated worse than the sheath and was mainly used for 
similar activities but by men who could not use a sheath (e.g. retracted penis); not 
good for seated activities.  
 Clamp: good for short vigorous activities like swimming/exercise. Most secure, least 
likely to leak, most discreet but almost all men described it as uncomfortable or 
painful. 
 Pads: good for everyday activities and best for night-time use. Most easy to use, 
comfortable when dry but most likely to leak and most uncomfortable when wet. 
 A preference for having a mixture of products to meet daytime needs; around two 
thirds of men were using a combination of pads and devices after testing compared to 
baseline.  
 
Conclusions 
 This is the first trial to systematically compare different continence management 
devices for men  
 Pads and devices have different strengths which make them particularly suited to 
certain circumstances and activities. 
 Most men prefer to 
use pads at night but would choose a mixture of pads and devices during the day. 
 Device limitations were important but may be overcome by better design. 
 
 
Key words: penile compression device; body worn urinal; sheath drainage system; 
King’s Health Questionnaire; quality of life.  A
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Introduction 
 
 
Prostate cancer is the commonest  male cancer in the UK.
1 
 Around 10-15% of men who 
undergo surgical or non-surgical treatment for prostate cancer will suffer lifelong urinary 
incontinence (UI).
2-4 
 UI has major negative effects on quality of life and social interactions
5-
11
 and is associated with long term morbidities such as skin injury, urinary tract infection, 
falls, and increased hospital stays.
12
 For those who do not regain continence, absorbent pads 
or alternative products and devices are required to maintain social continence.  
In addition to the usual choice of absorbent pads, other continence products include penile 
compression devices (clamp), sheath/condom drainage systems (sheath), and body-worn 
urinals (BWU).  In the UK the latter two are available on NHS prescription. However their 
market share is low compared to the use of absorbent products despite recommendations that 
men should be offered male devices as well as pads
12-14
 and evidence that men may prefer 
sheaths to pads.
15
  The limited research on the comparative efficacy, strengths and 
limitations, is an important barrier to alternate device use.   Thus, the objective of this study 
was to compare the performance of three continence management devices (penile clamp, 
sheath and  body worn urinal) and absorbent pads used by men with on-going UI following 
prostate cancer treatment.  The relative costs of providing the different products, and 
participants’ views on value-for-money were also investigated. 
Patients and Methods 
 
Participants: Community dwelling men living in the Southern Counties in England who had 
been treated for prostate cancer, had persistent UI > 1 year, currently used at least one 
absorbent pad per day, and had satisfactory manual dexterity to apply and remove the 
devices.  Exclusion criteria were: faecal incontinence and problems that might make the use 
of male devices unsafe i.e. a known latex allergy, reduced genital sensation and impaired 
cognitive function (MMSE < 27). Ethics approval was given by Southampton and South 
West Hampshire REC; NHS governance approval was obtained from each of the NHS Trusts.  
Written informed consent was obtained from each participant.  
 
Trial Registration  
The trial was registered with the UK Clinical Research Network (No. 8975) and can be found 
at:  
http://public.ukcrn.org.uk/Search/Portfolio.aspx?UKCRNStudyID=8975&SearchType=Any 
 
Trial Design  
 
The study was a randomised cross-over trial using Latin Squares method
16
 with each 
participant testing the three devices in random order day and night for up to three weeks 
(except the clamp, which is not suitable for night use).  A registered nurse expert in 
continence care visited participants in their homes at four data collection points.  Baseline 
data included demographics, continence status, measures of independence (Barthel Index
17
), 
cognitive function (Folstein Mini-mental test exam
18) and quality of life (King’s Health 
Questionnaire
19
).  Figure 1 shows trial the design.  A
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Primary Outcome: Overall Opinion Questionnaire 
 
The Overall Opinion Questionnaire was completed after all products had been tested; it was 
designed to elicit: 
 overall opinion (rated on a 10 point visual analogue scale) for day or night use 
 product acceptability  ( not acceptable /poor/ acceptable / good) 
 advantages and disadvantages of the test products and the absorbent pad in regular use 
by the participant 
 stated preferences (which products men planned to use post-test).  
 
There were four secondary outcomes:  
 
1. Product performance questionnaires were based on a previously tested tool used in a 
study of sheath use
22
 and were piloted by seven men (5 using sheath or BWU; 2 using 
clamp) to ensure questions captured all relevant aspects of product performance.   
These were administered at the end of each product testing.  
 
2. Quality of Life measured by King’s Health Questionnaire (KHQ).  This is a widely 
used validated instrument and is suitable for men and women.
19,20
 KHQ has weighted 
scores for nine dimensions ranging from 0 (best)-100 (worst).  The lower the score the 
better the reported QOL. This data was collected at the end of each product testing 
and at 3 months post testing (Visit 5). 
 
3. Revealed preferences  (which products participants had actually been using vs 
planned use) and views about what the NHS should provide based on estimated cost 
to NHS of each device and pads, were obtained.   Data was collected at Visit 5.   
 
4. Perceived Value for Money was obtained through simplified questions following 
piloting of more complex versions. The costs of products derived from NHS Supply 
Chain catalogue
21
 and from online formulary data
22
 were disclosed to participants to 
see if awareness of relative costs affected their stated preferences.  Data was collected 
at Visit 5.  
 
Study Products (Figure 2) 
 
Pads: Participants used their current product supplied by the NHS.  This was included as the 
baseline norm with which all participants were familiar.  Our intent was to assess the 
perception of the test products relative to normal product use/standard of care.   
 
Sheaths: The three most commonly used brands based on prescription analysis data
23
 
,24
 were 
selected and participants were randomised to one of the three brands. Men with very light 
leakage had the option of connecting a valve to their sheath, rather than wearing a drainage 
bag. 
BWUs: These were fitted by representatives from the two UK suppliers of these products 
(SG&P Payne and Jade Euro Med Ltd.) as is normal practice.  If fitting of one BWU was not 
successful, the alternate was tried.   
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Clamps: The Cunningham clamp was selected because there is evidence that it is the most 
effective and is the only product with radiology testing of penile circulation.
24
  
 
Sample size Target sample was 80 men to allow for the detection, with about 80% power, of 
a difference of 30% in Overall Opinion scores for any pair-wise comparison of products with 
an overall significance level, of at most, 5% for all such comparisons.  
Randomisation:  Randomisation was determined using a computer generated list into 
random block sizes of 6. Participant assignments were given by the central study 
administrator to the local research nurse after consent and baseline data were obtained.  
Because of packaging, it was not possible to blind participants or research staff to products.  
 
Statistical Methods: Background characteristics were described using summary statistics.  
The Chi-Squared test was used when comparing any two groups (e.g. Light incontinence vs 
Moderate/Heavy incontinence pad users) with regard to categorical variables. The paired t-
test was used for assessing changes in continuous variables (e.g. number of pads used, 
product VAS score). The Friedman test was used for comparing the 4 products (Pads, BWU, 
Sheaths, Clamp) with regard to ordinal outcomes. When a statistically significant result was 
obtained, indicating that the 4 products did not all have the same ordinal outcome level, the 
McNemar test was used to compare each pair of products with regard to a binarised recoding 
of the ordinal outcome in question (a dichotomous grouping was selected in order to facilitate 
the readability of the final report). Repeated measures analysis of variance was used to 
compare the 4 products with regard to continuous outcomes such as VAS scores. Each pair of 
products was subsequently compared, with a Bonferroni adjustment to allow for multiple 
comparisons. The Spearman Rank correlation test was used for assessing the association 
between two ordinal variables, or between an ordinal variable and a continuous variable. 
Results 
 
Participants 
Data collection occurred between December 2010 and April 2012.  3547 men living in South 
East England were contacted by mail via Continence Advisory Services, Urology outpatients 
and prostate cancer charities (an unknown number were invited via email and face to face by 
these organisations).  302 were screened for eligibility and 74 recruited; 18 either withdrew 
or were withdrawn (Figure 3); 56 had complete data at the end product testing.  Baseline 
characteristics are summarised in Table 1. The participants were predominantly retired, 
independent men whose quality of life was adversely affected by incontinence.  Most had 
undergone radical prostatectomy (n=44); the others were TURP plus radiotherapy (n=2),  
HIFU (n=4),  radiotherapy (n=6).  Four men had had AUS inserted post radical 
prostatectomy.  All reported stress incontinence. Eighteen did not use continence products at 
night. At study entry, more than half had previously tried out sheaths, but few had used 
BWUs and clamps.  Men described their incontinence as ‘light’ or ‘moderate’ based on the 
number of pads used per day.  Overall mean pad use per day was 2.9 (SD 1.82) ,median 3.0 
(light incontinence 2.6 (SD 1.59), median 3.0; moderate incontinence 3.40 (SD 2.14, median 
3.0).   
 
Products 
 
Overall Opinion after testing all products 
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On a Visual Analogue Scale (Table 2A) pads were rated significantly higher than the other 
products in all situations.  When comparing acceptability --- either ‘good/acceptable’ versus 
‘poor/not acceptable’ --- pads were rated most highly compared with sheaths (p=0.031), 
clamps (p=<0.000) and BWUs (p=<0.000) (Table 2B). Sheaths were more highly rated than 
BWUs (p=<0.014).  For the criterion of ‘good/acceptable versus ‘poor/not acceptable’, pads 
and sheaths are rated very similarly. Pads were significantly more acceptable than all the 
other products for day use at home; significantly more acceptable than BWU and clamps (but 
not sheaths) for day use away from home; sheaths were more acceptable than BWU for day 
home and day away use.  At night pads were the most acceptable product.   
 
Product performance  
 
Feedback on product performance immediately after testing each product indicated some 
important differences between the four designs (Table 3).  Although pads were rated highest 
for overall opinion, they were reported to leak the most but were the easiest product to apply 
and remove, and scored highly for comfort when dry (but not when wet). The sheath was 
generally rated better than the pad for leakage, odour, comfort when wet, ease of carrying and 
disposal, and better than the BWU for comfort when dry, comfort when wet, visibility, odour, 
ease of putting on and ease of carrying. The BWU was rated as being better than pads for 
comfort when wet, but worse than the sheath in all other aspects. It was also significantly 
worse than the sheath and clamp for impact on self-image. The clamp was rated better than 
the other three products for security, leakage and low impact on clothing choice, ease of 
application, better than the BWU and sheath for keeping the skin dry, and superior to pads for 
odour control. However the clamp caused the most pain. 
 
Stated and actual preferences 
 
When men were asked which products they planned to use in the future, most selected 
combinations for day use, but pads were the preferred product at night (Table 4). The 
proportion of men opting for a combination of products in the day was higher after testing all 
products than at baseline (n= 37, 66.6% vs. 5, 8.9%), the most popular combination being a 
pad and sheath (14/56 men) for use when away from home 
 
Pad use in the day was lower at 3 month follow up than pre testing (mean (SD) pads per week 
(13.3 (10.8) vs. 16.7 (10.5), p =0.01), confirming some switching to other products, but there 
was no significant difference at night (5.1 (4.1) vs. 5.0 (4.2), p = 0.87).  The number reporting 
using a mix of products in the day had, however, dropped slightly from 37/ 56 (66%) 
immediately post testing to 32/55 (58%) three months later, but was still higher than at 
baseline (n=5).   
 
Post study, ethical approval was received to contact participants to review their product use.  
At twelve months, 36 men were traced of whom 19 (53%) stated they were still using 
combinations of products.  
 
Quality of Life (Table 5) 
Quality of life was measured at baseline, after each test period and at 3 months post testing.   
There was a significant improvement in quality of life (KHQ) immediately after trying out 
the sheath (score change -4.0, p=0.001, 95% CIs -6.3 to -1.7) and the BWU (score change  
-2.25, p=0.004, 95% CIs -3.8 to -0.7). There was no difference in quality of life scores after 
trying out the clamp or for any devices at 3 month follow up compared to baseline. 
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Descriptive comments 
 
Participant comments reinforced the preference for a mix of products and the value of having 
a selection available.  
 
“If I am at home and not engaged in anything too physical I just have underpants on. Maybe 
in the evening particularly if I have a drink I may wear some padded underpants...If I play 
golf I wear the sheath system….I have found that if I go out for the evening for a meal or 
maybe a couple of drinks at a gathering….I do tend to wear the sheath.” 
 
“None of the three appliances in the trial are as comfortable or convenient to use as pads; it is 
always pleasant to use a fresh pad; none of these appliances has this feeling. However, they 
do have advantages, in particular the potential to enable me to go for longer periods without 
having to change something such as a pad, e.g. a reasonably long walk or shopping, or 
several hours working in the garden. Even the two hours of the clamp can provide this to a 
small extent when I am being active, but the two hour limit means using some kind of timer 
to avoid over-running by too long…….in summary, I need a reason to use one of these 
devices over and above simply using a pad.” 
 
Strengths and limitations of each product are summarised in Table 6.  
 
Overview of health economic analysis 
 
Views about value-for-money of products (Table 7) 
First men were asked about use of pads and sheaths in various combinations for day use. The 
proportion stating the NHS should only provide pads (the cheapest option), was 40%. 
Immediately after testing all products and when the relative costs were still not known by 
participants, less than 25% would select pads alone and higher proportions chose more 
expensive combinations of pads and sheaths.  Three months later, when the costs were 
disclosed, over 70% thought the NHS should offer BWU and clamps to men, although much 
smaller proportions had reported using these products post testing or stated they would use 
them in the future. 
 
Adverse Events  
Reported adverse events were: skin reddening from the sheath (n=1); blister from BWU 
straps (n=1); and pain from penile compression device (n=47). Apart from pain, the low 
incidence could be due to the short length of use of each device and the support of a research 
nurse expert in continence management. 
 
Discussion 
This is the first clinical trial comparing performance of three male-specific devices for 
continence management and absorbent pads, and the first to examine user preferences 
immediately after testing and actual use (revealed preferences) several months later.  It is also 
the first published trial of body worn urinals (there have been clinical trials of urinary 
sheaths,
15,25  
absorbent pads,
26
 and penile clamps
24,27 
) and thus provides valuable clinical 
information on the differences between products, their strengths and limitations, and the need 
for individual support in choice of products for different activities.  A
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Of note are the substantial differences found in product performance and an important finding 
was the extent to which men found benefit from using a mix of products, often for different 
activities or circumstances. Around two thirds continued to use at least one device in addition 
to absorbent pads 3 months after testing.   
 
Most men in this study had light incontinence (determined by usual pad size) and all had been 
treated for prostate cancer.  This population differs from that reported by Chartier-Kastler
15 
 
who studied men with moderate/heavy incontinence (any cause) when wearing a sheath 
drainage system compared to their usual pads.  Participants in that study reported 
significantly better quality of life with sheaths and around two thirds preferred sheaths to 
pads.  We also found that men had significantly better quality of life initially following sheath 
testing (and BWU ) and around a third stated that they preferred to use a sheath but almost 
always in combination with pads and/or other devices. Our study supports the provision of 
sheaths but usually as part of a mix with other pads and devices rather than as an alternative.    
At study entry, 55% had used at least one of the devices (usually a sheath). Most who had 
tried devices had done so with apparently little, if any, support from HCPs; 97% reported 
fitting their own devices unaided. Study participants received expert guidance to ensure 
maximum success with each device and the acceptability of devices probably indicates the 
importance of good fitting and support.
12
 
Typically men in the UK do not pay for their pads or devices as they are supplied freely 
within the tax-funded NHS. However, cost sensitivity was shown by some participants. 
Immediately after product testing, when relative prices were not known to them, men stated 
that they would prefer the more expensive containment option of a mix of sheaths and pads.  
When relative costs were revealed three months post testing, most men agreed that the NHS 
should provide BWU and clamps as well as pads and sheaths.  
 
Important short-comings of device designs were revealed. The BWU design was generally 
less successful than the sheath and most men who could use a sheath would do so in 
preference to the BWU. Sheaths are difficult to use for men with a short or retracted penis 
and, although the BWU is designed for this purpose, men experienced difficulty in keeping 
the BWU in place. The BWU design was also considered the most unappealing design with 
the worst impact on self-image. The clamp had important strengths in continence control but 
also caused discomfort and pain.  A substantial proportion of men may not receive good 
information and advice about products. To help provide men with fitting information our 
team produced a video on successful sheath application.
26
 
 
Limitations  
 
Despite the extensive mail-out, recruitment target was not achieved in the time and resources 
available. Not all continence pad delivery services were able to identify men who had 
prostate cancer and some men did not participate because of fear of jeopardizing their pad 
supply.  Not all urology services routinely asked men whether they experienced continence 
problems and thus were unable to assist with recruitment.     
 
Most men had light incontinence. A study focusing on men with moderate/heavy 
incontinence may show that the preferred product combinations are different.  
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No validated tool for assessing quality of life of pad or device use is available and although 
we carried out a brief validation of our questionnaire and based it on one that had been 
previously tested for reliability in another study, our questions may not have included all the 
items of importance to pad/device users.  
 
Recommendations for research   
 
 Development and 
design of improved products for management of incontinence in men.  Taking 
advantage of modern materials and technologies conducted in partnership with users 
to ensure their needs and preferences are accommodated.   
 Development and 
validation of a reliable instrument for measuring the performance and quality of life 
implications of different designs. 
 
Recommendations for practice 
 
The findings have several implications for clinical practice. Better information and advice 
about continence products for men is needed to inform and support health care professionals 
and patients.  During routine follow-up of prostate cancer treatment, men should be asked 
about the presence of urinary incontinence, and how it affects their daily life.  Containment 
products can be tailored to men’s needs depending on the sport/leisure/work and social 
activities that they do, or would like to do. Men should be offered information about all types 
of absorbent pads and male devices and how to obtain products to try.  In general, a sheath 
system should be tried before a BWU, but individual advice on fitting is required to maximise 
chances of success.  Clamps are an effective option, but for short periods only, and provided 
cognitive ability, manual dexterity and bladder and genital sensation enable safe use.   
 
Conclusion 
 
The three devices and absorbent pads have different strengths and limitations that make them 
more (or less) suitable for particular activities. Most men prefer to use a combination of 
devices and pads in order to meet their lifestyle needs. Where products are provided by health 
services, combinations of devices and absorbent products should be offered together with 
skilled fitting and support, in order to provide optimum continence management. 
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KHQ = Kings Health Quality of Life questionnaire 
MMSE = Mini Mental State Exam 
PPQ = Product performance questionnaire 
Visit 1: Baseline assessment:  
Demographics, continence status, Barthel Score, MMSE and KHQ 
Product Testing 
Product Testing 
Product Testing 
Randomised centrally in blocks of 6 
Visit 4:  PPQ + Interview + KHQ and 
End of testing:  
 Self-reporting of overall opinion for 
each device and usual pads 
 plans for future product use (stated 
preference) 
 
 
 
 
Figure 1:  Crossover trial design and progression through the study 
Week 1-3 
Week 4-6 
Week 7-9 
Week 9 
Visit 5:  
 Self-reporting of product use during previous 3 months (revealed 
preference) 
 Value for money for each of the 3 devices (sheath, BWU and clamp) 
 KHQ 
3 months 
post-test  
Postal Survey: Self-reporting of product use to establish on-going 
preferences. 
1 year post-
test – ethical 
approval 
Visit 2: PPQ + Interview + KHQ 
Visit 3: PPQ + Interview + KHQ 
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Figure 2: Details of products used in the study 
 
 
 
Product type 
 
 
Design 
 
Brand (Dispensing 
Appliance Contractor 
(DAC)) 
 
 
Pad 
 
 
 
 
 
 
 
Varied - Participant’s current pad 
(standard care) 
 
NHS Trust or self-purchase 
 
Sheath 
 
 
One piece (integral adhesive): 
 Attached to body-worn 
drainage bag or catheter 
valve 
 Body-worn bag 
supported by straps / 
support garment 
 Night bag + stand 
supplied as necessary 
 
Conveen Optima (Coloplast 
Ltd.) 
P-Sure (Manfred Sauer) 
Clear Advantage (Rochester 
Medical) 
(shorter length versions used 
when available) 
 
BWU 
 
 
 
 
Rubber cone + flange (One or 
two piece): 
 Attached to body-worn 
drainage bag or tap 
 Body-worn bag 
supported by straps / 
support garment 
 Night bag + stand 
supplied as necessary 
 
Mark 6 (SG & P Payne) 
Model 101 & 106 (Jade Euro-
Med) 
 
 
Clamp 
 
 
 
 
 
 
 
Hinged clamp made from soft 
sponge rubber and metal. 
Available in two sizes. 
 
Cunningham design clamp 
(SG&P Payne) 
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Figure 3: Consort Diagram 
 study C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reasons for ineligibility  N 
No history of prostate cancer 116 
Non-surgical treatment only (prior to change in exclusion 
criteria to include men having non-surgical treatments 
only) 
5 
Cognitive impairment 9 
Ill health 13 
Very light or no leakage 30 
Faecal incontinence 9 
Impaired bladder sensation 1 
Unwilling to try products (Clampx3;BWUx1;generallyx28) 32 
Not currently using absorbent pads 6 
Reason unknown 7 
Total 228 
302 men assessed for eligibility 
228 ineligible (see below for detail) 
 
56 men completed 
 
74 consented to take part 
Mail out (post + email) to  
N= > 3547 men 
Southern counties of England (Continence 
Advisory Services - pad databases, 
Urology clinics, prostate cancer charities)  
18 men withdraw after consenting to take 
part: 
 
6 withdrew before testing started 
 1 man  decided his 
incontinence was too light to 
bother with the products 
 1 man who had a job felt he 
was  too busy to participate 
  2 men failed the mental test 
score at visit1 
 1 man was discovered not to 
have had prostate cancer after 
consenting 
 1 man declined to give a 
reason 
 
12 withdrew during testing 
 8 due to ill health 
 1 incontinence cured following  
continence surgery 
 1 man lived alone, very frail 
and unable to manage the  
devices 
 1 man lived alone, depressed 
and unable to cope with the 
process 
 1 man tried BWU and clamp 
but he felt unable to cope with 
sheath 
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Table 1: Participant characteristics-demographics, health, quality of life and incontinence (N=56 
men)  
Continuous variables Mean SD 
Age (years) 
 
72.2 
6.6 
(Range 54-85) 
Barthel score. 0= total dependence, 100 = independent) 92.5 3.6 
KHQ max 100; high score = low continence-related QOL 39.6 11.5 
Time between first treatment and entering study (years) 7.5 5.1 
 
Frequencies: n (%) 
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Employment  
N=41 responses 
Retired 
35 (85.4) 
Full-time 
1 (2.4) 
Part-time 
4 (9.8) 
Seeking work 
1 (2.4) 
Type of 
incontinence 
 
 
Stress Urinary Incontinence(SUI) 
38 (67.9) 
Mixed 
(SUI + Urge incontinence) 
18 (32.1) 
Severity of 
incontinence 
 
 
Light 
38 (67.9) 
 
Moderate / 
heavy 
18 (32.1) 
Light = using small insert, pouch, leaf 
Moderate/heavy if using  medium/large 
insert, diaper, pull-up 
Primary 
treatment for 
prostate cancer 
Radical Prostatectomy 44 (78.5) 
TURP + RT  2 (3.5) 
HIFU 4 (7.1) 
Radiotherapy 6 (10.7) 
 
Typical product 
use: 
Pads only Sheaths  and pads 
Day 48 (85.7) 8 (14.2) 
Night : None, n= 
18 (32.1) 
35 (62.5) 3 (5.4) 
Previous product 
use:  
Tried sheath? Tried BWU? Tried clamp? 
Had help with 
fitting these 
products (N=34) 
YES: 31 (55.4) 
NO: 25 (44.6) 
YES: 5 (8.9) 
NO: 51 (91.9) 
YES: 3 (5.4) 
NO: 53 (94.6) 
YES: 1 (2.9) 
NO: 33 (97.1) 
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Table 2A & 2B: Overall opinion after testing all products  
 
 
* Repeated measures ANOVA to test the null hypothesis of no difference in means between the 4   
  products 
** N is less than 56 (day use home or away) and 38 (night use) due to missing data 
 
Table 2B: Acceptability 
  N* Not acceptable 
/ Poor 
Acceptable / 
Good 
Paired comparisons 
Significances (p values**) 
n % n % 
Day 
home 
Pads 56 4 7.1 52 92.9 Pads vs. BWU: 0.0005;  
Sheath: 0.031; Clamp: 0.0005 
BWU vs. Sheath: 0.014; Clamp: 0.361 
Sheath vs. Clamp: 0.405 
BWU 56 29 51.8 27 48.2 
Sheath 53 14 26.4 39 73.6 
Clamp 54 22 40.7 32 59.3 
Day 
away 
Pads 56 10 17.9 46 82.1 Pads vs. BWU: 0.0005; Sheath: 0.21; 
Clamp: 0.001 
BWU vs. Sheath: 0.010; Clamp: 0.571 
Sheath vs. Clamp: 0.11 
BWU 53 34 64.1 22 33.9 
Sheath 53 17 32.1 36 67.9 
Clamp 54 29 53.7 25 46.3 
Night Pads 44 4 9.1 40 90.9 Pads vs. BWU: 0.0005; Sheath: 0.019 
BWU vs. Sheath: 0.013 BWU 33 28 84.8 5 15.2 
Sheath 31 15 48.4 16 51.6 
 
* N is less than 56 (day use home or away) and 38 (night use) due to missing data 
** Paired comparisons between each pair of products using McNemar’s test 
 
 
 
 
 
Table 2A: Visual analogue scale  Range: 0 (worst opinion) – 10 (best opinion) 
 
 N Pads BWU Sheath Clamp Significance 
P*   Mean SD Mean SD Mean SD Mean SD 
Day 
home 
51** 7.56 1.64 4.10 3.07 5.61 3.37 4.61 3.42 <0.0005 
95%CI 7.10 to 8.02 3.23 to 4.96 4.69 to 6.53 6.64 to 5.57 
Day 
away 
51** 7.09 2.16 3.43 3.04 5.86 3.62 3.84 3.37 <0.0005 
95%CI 6.48 to 7.70 2.58 to 4.29 4.85 to 6.88 2.89 to 4.72 
Night 28** 7.84 2.40 1.89 2.39 4.46 3.81 Not relevant <0.0005 
95%CI 6.91 to 8.77 0.96 to 2.82 2.98 to 5.94 
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Table 3: Summary of product performance (daytime) (% of responses indicating agreement with 
statement) 
N=56  Pad as 
baseline/norm  
% 
Sheath 
% 
BWU 
% 
Clamp 
% 
Security 
 
Always feels secure  46 38 32 68 
Impact on clothing 
 
Product never affects 
clothing choice  
38 42 38 68 
Pain during use 
 Never experience pain  75 58 35 11 
Leakage  
 
Product never leaks  21 49 36 75 
Impact on  physical self-
image 
 
None  48 57 39 62 
Impact on feelings of 
masculinity 
 
None  55 74 63 62 
Ease of putting on 
 
Good  84 43 25 51 
Ease of taking off 
 
Good  84 24 32 48 
Ability to keep skin dry 
 
Good  34 48 35 66 
Kindness to skin 
 
Good  43 27 29 27 
Comfort when dry 
 
Good  77 64 38 n/a 
Comfort when wet 
 
Good  5 45 24 n/a 
Discreetness  to do with 
visibility 
 
Good  48 54 31 41 
Discreetness to do with 
odour 
 
Good  38 69 53 70 
Ease of disposal 
 
Good  38 65 n/a n/a 
Ease of carrying 
 
Good  35 65 38 78 
Storage of spare products 
 
 
Good  
46 73 43 84 
 product performs significantly better for that characteristic  than one, two or three of the other product(s) 
 product performs significantly worse for that characteristic  than one, two or three of the other product(s) A
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Table 4: Preferred products after testing all products 
 
 N Pads only Pads and other Other(s) only 
  n % n % n % 
Day 
home 
56 13 23.2 37 66.1 6 10.7 
    
Pads & Sheath (9); Pads & BWU (5); 
Pads and Clamp (9); Pads, Sheath, 
Clamp (5); Pads, Sheath, BWU (2); 
Pads, BWU, Sheath (1); all 4 (6) 
 
 
BWU (1);  Sheath (2);  
Sheath &Clamp (2);  
Sheath & BWU (1) 
Day 
away 
56 8 14.3 37 66.1 11 19.6 
    
Pads & Sheath (14); Pads & BWU 
(8); Pads and Clamp (4); Pads, 
Sheath, Clamp (7); Pads, BWU, 
Sheath (1); Pads, BWU, Clamp (1); 
all 4 (2) 
 
 
BWU (2);  Sheath (4);  
Sheath &Clamp (3);  
Sheath & BWU (1); 
BWU & Clamp (1) 
Night  45 44 99.8 1 0.2 0  
    Pads & Sheath  
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Table 5: King's Health Questionnaire Score Range: 0=Best to 100=Worst QOL 
 
  
Mean score at baseline 
 
Mean score after 
 testing device 
Difference between 
the means (95% CI) 
Significance 
<0.0005 
 
Sheath 
 
39.95 35.95   -4.0  (-6.36, -1.73) p=0.001 
 
BWU 
 
39.23 36.98   -2.25 (-3.76,-0.74) p=0.004 
 
Clamp  
 
39.13 37.83 -1.29 (-2.98,0.4) 
 
p=0.131 
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Table 6: Product strengths and limitations based on summary of subjective comments 
 
  
Pad 
 
 
Sheath + bag 
 
BWU 
 
Clamp 
Strengths  Easy to apply & 
remove 
 Comfortable when 
dry 
 Kind to skin 
 Best for night use 
 Used for long 
periods without 
changing 
 Easy to store, low 
risk of odour 
 Discreet emptying  
 
 Could be used for 
long periods without 
changing 
 Washable 
 
 Secure 
 Simple to remove 
 
  
Limitations  Bulk, leakage, 
odour 
 Moves around in 
clothing 
 Frequent changing 
 Disposal & change 
in public toilets  
 Uncomfortable 
when wet  
 
 
 
 Poor for penile 
retraction 
 Can fall off  
 Difficult to 
apply/painful to 
remove  
 
 
 
 Cumbersome/ 
 Chafing of straps 
 Will leak in certain 
positions – esp.  
sitting down 
 Penis can slip out 
 
 Pain/discomfort  
 Can only be worn for 
short periods 
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Table 7:  Views on value-for-money of products 
a) PADS and SHEATHS 
Information 
given to 
participants 
about costs 
 Most men receiving continence products from the NHS are given only pads. On average, if 
they are only using pads during the day, they are given 3 pads per day. This costs the NHS 
about £15 per month 
 The cost to the NHS of providing pads, and sheaths and accessories for use three times per 
week is about £42 per month 
 The cost to the NHS of providing only sheaths and accessories for daily use is about £58 
per month 
 The cost of sheaths is based on manufacturers’ recommendations (i.e. one sheath per 24 
hours) irrespective of whether sheaths are used exclusively or in combination with pads 
Question 
asked 
Bearing in mind the relative costs of these options, choose one option that you think the NHS 
should provide: 
Responses 
N=47 
Product for day use  Monthly cost to 
NHS 
Number (%) choosing 
option  
Only pads (no sheaths) £15 19 (40.4%) 
Sheaths on 3 days, pads on 4 days £42 11 (23.4%) 
Only sheaths (no pads) £58 2 (4.3%)
 
Sheath + one pad every day  £63 15 (31.9%)
 
b) BWU 
Information 
given on costs 
To provide a man with a body worn urinal costs the NHS about £68 for a urinal plus about 
£1.80 per bag used; manufacturers state a BWU can be expected to last about 6-12 months if 
used regularly, longer if less frequently.   
Question  Select the statement that best describes your views about BWU: 
Responses 
N=52 
I think the NHS should offer men only the body worn urinal for day 
use (i.e. The NHS should not provide pads or sheaths) 
1 (1.9%) 
I think the NHS should offer men the body worn urinal for day use in 
addition to other products such as pads and sheaths 
36 (69.2%) 
I think the NHS should NOT offer men the body worn urinal for day 
use 
15 (28.8%) 
c) CLAMP 
Information 
given on costs 
To provide a man with a clamp costs the NHS about £30 per clamp, and manufacturers 
indicate that a clamp can be expected to last for up to 12 months or longer depending on 
frequency of use.  Reminder that the clamp is only for day use.  
Question  Select the statement that best describes your views about the clamp: 
Responses 
N=51 
I think the NHS should offer men the clamp for day use in addition 
to other products such as pads and sheaths 
39 (76.5%) 
I think the NHS should NOT offer men the clamp for day use 12 (23.5%) 
Notes on 
derivation of 
costs 
All costs were rounded to make comparisons easier. 
Pad cost estimates from prices in the NHS Supply Chain catalogue
23
, and based on information 
from men recruited early in the study about the number and type of products they received 
from continence services. Median price (14p per pad) in Rothwell absorbency bands 7-8 (light 
– moderate absorbency) was used. Most men reported using 3 pads per day (day use only). 
The average costs of BWU, sheaths and clamps were taken from the Online Formulary data
21
: 
sheaths assumed 1 per day @£1.55 each; leg bags , 1 per week @ £2.50; bag support garments 
, 1 every 2 weeks @ £2 each. Clamp (Cunningham): priced at £26. Fitting costs of sheaths and 
clamps were not included. This would usually be done by district nurses (NHS unit costs of 
home visit for 30 minutes: £35 [26]. BWU: mean of two available brands: £67, includes price 
of fitting by dispensing appliance producer. Leg bags and support garments are extra, as for 
sheaths.   
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